The three requirements the foreword sets out — closing off the "true but misleading," implementing balance on the page, and guaranteeing verifiability through structure — are not stylistic rules. They are the concrete expression of an ethical stance. The three pillars directly reject the idea that legal compliance is sufficient. Even when a statement is factually accurate, if the reader forms a false conviction, that is an ethical failure.
The three pillars are not independent rules — they form a single ethical position, supported from three directions. Closing off misunderstanding defines what is prevented. Balance defines what must be built into the page itself. Verifiability defines what structure must guarantee. Only when all three are in place does a material become a genuine expression of scientific integrity.
01Closing off the "true but misleading" — ethics one level above accuracy
Stating facts and not misleading the reader are two different questions. Present the relative risk reduction prominently while pushing the absolute risk reduction to an inconspicuous location, and every number remains accurate while the reader's judgment is distorted. Describe a trial in which the primary endpoint failed to reach significance while foregrounding a post-hoc subgroup finding in the headline, and the reader will mistakenly believe evidence of efficacy exists. This is the "factually accurate yet misleading" pattern.
The Creation Guide is most alert to this pattern precisely because it is hard to detect. A falsehood can be verified. But "guidance through arrangement, selection, and truncation" is invisible as a problem, because the underlying material is correct. That is why the ethical obligation extends beyond "is this accurate?" to "does this mislead?"
How this is put into practice
The practical means are data disclosure and context preservation. Show absolute and relative risk reductions side by side. Do not omit confidence intervals. Start a graph's y-axis from zero. Each of these is an operation on "how facts are placed" to prevent misunderstanding. The core of this pillar is refusing to omit information that, while not technically a lie, would distort the reader's picture if absent.
02Implementing balance on the page
Promotional materials for prescription drugs are created to communicate efficacy. For this very reason, safety information is prone to being treated as secondary — small type, a corner location, a footnote. Technically "included" does not mean "communicated."
The Creation Guide requires warnings and contraindications to be displayed in Gothic type at 10 points or larger, with attention to framing, background color, and type color. The reasoning is that physical quantities — type size, placement — determine the quality of information transmission. If efficacy figures occupy the prominent position, the path to safety information must be equally prominent. "The balance pillar" means this, at the level of page layout.
The asymmetric duty — disclose even what harms your own interests
Balance demands something further. When pharmacological properties or toxicological findings suggest the possibility of adverse reactions in clinical use, they must be recorded — even when doing so works against the manufacturer's commercial interest. This applies to the safety pharmacology and toxicity sections of the material.
Presenting favorable information and omitting unfavorable information is the asymmetry that distorts the reader's judgment. The Creation Guide reverses that asymmetry. For safety-side information, it imposes a duty to disclose that overrides commercial motivation. This is the core of the asymmetric duty.
03Guaranteeing verifiability through structure
Claims made in a material must be checkable after the fact. "Which trial and which analysis did this efficacy figure come from?" "Which version of the package insert is being referenced, and when was it current?" A material that cannot answer these questions leaves its evidentiary basis floating in mid-air.
Verifiability is achieved by attaching source references, version numbers, and dates to all claims. The key references section retains bibliographic details. When clinical data come from regulatory submission materials, that fact is stated. The date of preparation or revision appears at the close. These are unobtrusive entries, but together they keep the path back to primary sources perpetually open.
Applied to meta-analyses
Verifiability is stated most concretely in the requirements for meta-analyses. The databases searched, the search keywords, the number of records identified, the number of articles assessed for eligibility, the number excluded and the reasons for exclusion — all of this is required so that "where was searched, what was selected, and what was dropped" can be traced later. A meta-analysis that does not disclose its search process offers no means to verify whether exclusions were made by design.
04The three pillars — a structural overview
| Pillar | What it prohibits / requires | What it protects |
|---|---|---|
| Closing off the "true but misleading" | Prohibits guidance by arrangement, selection, and truncation; requires preservation of context | The reader's ability to reach an accurate judgment |
| Implementing balance on the page | Prohibits physical subordination of safety information; requires disclosure of unfavorable findings | Safety information that is not merely present but actually communicated |
| Guaranteeing verifiability through structure | Prohibits claims without source, version, or date; requires a traceable path to primary sources | The ability to verify any claim after the fact |
05What the three pillars ask
What the three pillars share is a positive purpose — not merely a lower bound of "what must not be done" but an active commitment to supporting the judgment of healthcare professionals. The physicians and pharmacists who receive these materials are making prescribing decisions. The quality of their decisions has direct consequences for patients. A material designed on the principle of "no legal problem, no problem" degrades the quality of those decisions.
The ethics the three pillars demand provide a decision-making framework that prioritizes scientific integrity when it conflicts with commercial motivation. Not misleading, maintaining balance, ensuring verifiability — these are the minimum conditions for prescription drug information to merit trust, and at the same time they are the words that most concisely capture the spirit of the foreword as a whole.
Closing off the "true but misleading," implementing balance on the page, guaranteeing verifiability through structure — the three pillars are not independent rules but three faces of a single ethical position. The temptation to omit unfavorable information, to push safety to small type in a corner, to dress up a claim without disclosing its source — commercial motivation presses on ethics from precisely these three directions.
The three pillars of the foreword are designed to block that erosion through structure. Every specific rule in the chapters that follow — the disclosure requirement at the opening of post-hoc analyses, the minimum type size for warnings, the search-process disclosure in meta-analyses — is a translation of this ethical stance into individual decision points.